Bindarit

Bindarit

SCHEMBL371677

CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(=O)O.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 15/20 0.98
MCTS1 Q9ULC4 10/20 0.54
SLC16A1 P53985 9/20 0.54
CNR1 P21554 1/20 0.48
ACHE P22303 1/20 0.48
CNR2 P34972 1/20 0.48
F2RL3 Q96RI0 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
SSTR4 P31391 1/20 0.44
SCN8A Q9UQD0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bindarit SCHEMBL29387325 0.99 SLC16A3 (1.00) SLC16A3MCTS1SLC16A1CNR1ACHE
Bindarit SCHEMBL187885 0.99 SLC16A3 (1.00) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL928717 0.92 SLC16A3 (0.87) SLC16A3MCTS1SLC16A1HDAC3HDAC1
SCHEMBL928508 0.92 SLC16A3 (0.87) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL15372292 0.91 SLC16A3 (0.84) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL927983 0.90 SLC16A3 (0.83) SLC16A3MCTS1SLC16A1CNR1CNR2
SCHEMBL1650741 0.89 SLC16A3 (0.83) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL927364 0.89 SLC16A3 (0.81) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL927459 0.88 SLC16A3 (0.81) SLC16A3MCTS1SLC16A1CNR1ACHE
SCHEMBL927411 0.88 SLC16A3 (0.80) SLC16A3MCTS1SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2409698-B1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition ACRAF (IT) 2015-01-21 EP disclosed
US-8846745-B2 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2014-09-30 US disclosed
EP-2097080-B1 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS ACRAF (IT) 2013-02-20 EP disclosed
US-20120283307-A1 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2012-11-08 US disclosed
US-8198310-B2 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.P.A. (IT) 2012-06-12 US disclosed
EP-2409698-A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2012-01-25 EP disclosed
CN-101541323-B Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels ACRAF 2012-01-04 CN disclosed
US-20100069456-A1 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) 2010-03-18 US disclosed
CN-101541323-A Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels ACRAF (IT) 2009-09-23 CN disclosed
EP-2097080-A2 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) 2009-09-09 EP disclosed
WO-2008061671-A2 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283307-A1 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS LIPC, PNLIP, GPR119 SLC16A3 1443/4885MCTS1 4324/4885SLC16A1 1778/4885
US-20100069456-A1 USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS INSR, GPR119, MTTP SLC16A3 2333/4885MCTS1 4545/4885SLC16A1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.